TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02805699
Drug: Baofeikang Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
Study: NCT02805699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
Study: NCT03911570
Drug: Glucosamine Sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapy with the prescription formulation of crystalline glucosamine sulfate
Study: NCT03798561
Drug: ASN008 TG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN008 TG
Study: NCT00890968
Drug: Placebo DuraPeel
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel; once daily (nightly); total duration: 4 weeks
Study: NCT04799782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo pill before bed-time
Study: NCT03596125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os: jelly tablets Intravenous Route: Glucidion G5
Study: NCT00564629
Drug: Intravenous acetaminophen plus oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 gm IV acetaminophen
Study: NCT00564629
Drug: Oral acetaminophen plus IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 g PO APAP
Study: NCT03280550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Study: NCT02575482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01466725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00668525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral administration, once daily dosing for 8 weeks
Study: NCT03991377
Drug: Treatment as usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
Study: NCT02029430
Drug: 100 mg/m2 aldoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02029430
Drug: 150 mg/m2 aldoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03259035
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of q2weekly FOLFOX, or
Study: NCT03259035
Drug: Capox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of q3weekly CAPOX
Study: NCT03787004
Drug: CNTX-6970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose CNTX-6970
Study: NCT01187212
Drug: Capecitabine/Cisplatin + Sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
Study: NCT00882674
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
Study: NCT02681887
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
Study: NCT02681887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet identical to circadian
Study: NCT00911664
Drug: No supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control
Study: NCT00277472
Drug: Valsartan/Hydrochlorothiazide
Normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/12.5 mg taken once daily orally
Study: NCT00004697
Drug: choline chloride
Normalized name: Choline Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03806595
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
Study: NCT00404768
Drug: GSK221149A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg/h and 12 mg/h
Study: NCT00404768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo to Drug
Study: NCT00906256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00717470
Drug: Prograf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00717470
Drug: Advagraf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02255110
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
Study: NCT00296348
Drug: steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00375934
Drug: diclofenac potassium (XP21L)
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg capsule, every 6 hours
Study: NCT00375934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsule, every 6 hours
Study: NCT02980835
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
Study: NCT02980835
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
Study: NCT01266148
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
Study: NCT02625519
Drug: Urinary follicle-stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian stimulation with highly purified urinary follicle-stimulating hormone
Study: NCT02135640
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution
Study: NCT04646317
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% as placebo
Study: NCT01677611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02901717
Drug: Antibiotic lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
Study: NCT00744055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03191084
Drug: Placebo Marijuana
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
Study: NCT03836287
Drug: Sofpironium Bromide Gel, 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT03836287
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel
Study: NCT00002872
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03692910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 matching placebo capsule
Study: NCT00318838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
Study: NCT04689984
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin, pregabalin, or amitriptyline
Study: NCT00151411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01028209
Drug: [18F] PBR06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
Study: NCT03351322
Drug: ENERGI-F701
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENERGI-F701 are applied for treatment of hair loss.
Study: NCT04094506
Drug: ASP1948
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT02606773
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid in different ways and doses
Study: NCT02571361
Drug: Ibuprofen (400 mg x 4)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
Study: NCT02571361
Drug: Ibuprofen (200 mg x 4)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
Study: NCT02571361
Drug: Placebo (x4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given in 6 hour intervals the first 24 hours postoperatively
Study: NCT04003155
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT00920465
Drug: mifegyne and cytotec
Approvals — FDA: no, EMA: no, PMDA: no
Description: One day dosage versus two days dosage
Study: NCT02874794
Drug: LCZ696 (sacubitril/valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24/26mg, 49/51mg and 97/103mg oral, tablets.
Study: NCT02874794
Drug: Placebo of LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
Study: NCT00845910
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900mg/m2 po on days 1-14 of every 3 week cycle
Study: NCT01272934
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical gel 1%-4 times daily
Study: NCT03626753
Drug: Acetaminophen, (paracetamol) 500Mg Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours.
Study: NCT03626753
Drug: (Acetaminophen paracetamol) IV Soln 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
Study: NCT03626753
Drug: (Piroxicam piroxan) 20 MG Oral Tablet
Normalized name: piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 tablets of piroxicam (piroxan) administrated orally once per 24 hours.
Study: NCT03626753
Drug: (Piroxicam piroxan) 20Mg/1mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours.
Study: NCT03855189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray administered for 4 weeks.
Study: NCT01978912
Drug: KTP-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTP-001 is one time dose intradiscally.
Study: NCT01687517
Drug: Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
Study: NCT01334125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules once daily by mouth for 9 months
Study: NCT00803634
Drug: Standard of Care IV antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
Study: NCT01286259
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open label 500mg disulfiram per day by mouth for 14 days
Study: NCT00661063
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: bid - 12 weeks
Study: NCT03985319
Drug: YYD601 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
Study: NCT00688805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching capsule containing no active medication
Study: NCT03578900
Drug: Citric Acid based Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00853450
Drug: AZD6482
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion during a maximum of 5 hours
Study: NCT03710434
Drug: AZD4635 solid oral formulation - fasted
Normalized name: CORYDALIS SOLIDA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
Study: NCT03710434
Drug: AZD4635 solid oral formulation - fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
Study: NCT03710434
Drug: AZD4635 solid oral formulation variant 1 - fasted
Normalized name: CORYDALIS SOLIDA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
Study: NCT03710434
Drug: AZD4635 solid oral formulation variant 2 - fasted
Normalized name: CORYDALIS SOLIDA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
Study: NCT03710434
Drug: [14C] AZD4635 IV microtracer - fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
Study: NCT03174886
Drug: AADvac1 40 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy against neurofibrillary pathology.
Study: NCT03174886
Drug: AADvac1 160 µg
Normalized name: immunoglobulin G, human 160 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy against neurofibrillary pathology.
Study: NCT00966316
Drug: aspirin，chinese herbs；
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
Study: NCT02516059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Mundipharma Medical Company and Mundipharma Research GmbH \& Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
Study: NCT00766415
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, twice daily, 4 weeks treatment
Study: NCT00766415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00023452
Drug: RPT + INH once weekly for 3 months given by DOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old.~Therapy will be given by Directly Observed Therapy (DOT).
Study: NCT04091841
Drug: protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sachet of protein supplement to be mixed in with water used daily.
Study: NCT02528292
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
Study: NCT01358526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match OXN taken orally every 12 hours
Study: NCT02439346
Drug: BAY1143269 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
Study: NCT03832946
Drug: GB0139
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB0139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
Study: NCT03832946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered as inhalation once a day
Study: NCT01462344
Drug: ADVAIR 100/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
Study: NCT01462344
Drug: ADVAIR 250/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Study: NCT00928148
Drug: SPD465
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 or 75 mg once daily for 7 days
Study: NCT00928148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 7 days
Study: NCT00955877
Drug: Control: Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
Study: NCT03394924
Drug: EDP-305 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets daily for 12 weeks
Study: NCT03394924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets daily for 12 weeks
Study: NCT01702129
Drug: anti-EGFR immunoliposomes loaded with doxorubicin
Normalized name: Anti-egfr/c-met bispecific antibody emb-01
DrugBank: EMB-01 (DB16091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
Study: NCT03510481
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
Study: NCT03510481
Drug: artemether 20mg/lumefantrine 120mg (AL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
Study: NCT03283670
Drug: Placebo Gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Study: NCT04159831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT01235039
Drug: VIAject®25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
Study: NCT01235039
Drug: VIAject®7
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
Study: NCT03177993
Drug: 3 drug dose - IDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies